This is unpublished
Dr. Stephanie Lee
American Society of Hematology logo
December 6, 2022

Stephanie Lee receives Exemplary Service Award

The American Society of Hematology will recognize her for her exceptional service and dedication to the Society and the field of hematology through her tireless work leading ASH’s response to COVID-19.
Scroll for more
arrow icon
Back to top
Awards Faculty

Dr. Stephanie Lee, professor (Medical Oncology) is a 2022 recipient of the American Society of Hematology Exemplary Service Award. She is one of four awardees who will be recognized her their for their exceptional service and dedication to the Society and the field of hematology through their tireless work leading ASH’s response to COVID-19.

The Exemplary Service Award was established in 1998 to recognize individuals whose outstanding service, extending over a period of years, has significantly advanced the interests of the Society.

In March 2020, recognizing the urgent need to provide clinicians with resources to combat the pandemic, then-ASH President Dr. Stephanie Lee quickly mobilized the ASH COVID-19 content curation group to oversee the development and curation of resources on the ASH COVID-19 Resources website.

Under Dr. Lee’s leadership, the group went on to facilitate the development of clinically relevant Frequently Asked Questions (FAQ) articles authored by roughly 150 hematologists. The FAQs and website resources spanned various clinical, practice, and training-related topics; included links to journal articles, registries, institutional protocols, research grant opportunities, and clinical trials; and offered practical advice for restarting routine clinical practice.

As the pandemic evolved, so did the guidance – at first focusing primarily on infection prevention and treatment of patients with COVID-19 and various underlying hematologic conditions who were at heightened risk of severe infection. Later, FAQs were developed to address vaccination in the immunocompromised, treatment of dangerous blood clots triggered by COVID-19, and the use of convalescent plasma and antibody therapies.